The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091
Jay Lee, MD, University of California, Los Angeles, CA, gives an overview of upcoming practice-changing trials in the field of non-small cell lung cancer (NSCLC), including the Phase III CheckMate 816 trial (NCT02998528) of neoadjuvant nivolumab, an anti-PD-L1 monoclonal antibody, plus ipilimumab or chemotherapy in early stage, resectable NSCLC. A promising event-free survival and pathologic complete response (pCR) were observed in patients receiving nivolumab. Dr Lee additionally highlights the Phase III KEYNOTE-091 trial (NCT02504372) of adjuvant pembrolizumab in stage IB/II-IIIA NSCLC, which will potentially build on the results of the IMpower010 trial (NCT02486718). This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
